A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1142 | Th1020 | Asparaginase | QMSLQQELRYIEALSAIVET Full view | 255 | Ic | Cancer | Elspar | Merck & Co. Inc | Lyophilized plug or powder | Intravenous or Intramuscular. Intravenous method dose has higher risk of allergic reaction, so often a test dose is given first. | Antineoplastic Agents | L-asparagine |
| 1201 | Th1026 | Anistreplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ic | Hematological,Metabolic | Eminase | Wulfing Pharma GmbH | Dry powder | Intravenous infusion | Thrombolytic Agents, Fibrinolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
| 1260 | Th1037 | Botulinum Toxin Type B | MPVTINNFNYNDPIDNNNII Full view | 255 | Ic | Neurological Disorder | Myobloc | Solstice Neurosciences | Clear and colorless to light-yellow sterile injectable solution | Injection | Antidystonic Agents | Vesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
| 1261 | Th1037 | Botulinum Toxin Type B | MPVTINNFNYNDPIDNNNII Full view | 255 | Ic | Neurological Disorder | Neurobloc | Solstice Neurosciences | Clear and colourless to light yellow solution | Intramuscular Injection | Antidystonic Agents | Vesicle-associated membrane protein 2,Vesicle-associated membrane protein 1,Synaptotagmin-2 |
| 1288 | Th1042 | Collagenase | MKRKCLSKRLMLAITMATIF Full view | 255 | Ic | Hematological | Cordase | N.A. | N.A. | N.A. | N.A. | Collagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
| 1289 | Th1042 | Collagenase | MKRKCLSKRLMLAITMATIF Full view | 255 | Ic | Hematological | Santyl | Advance Biofactures Corp | Sterile enzymatic debriding ointment | External use only | N.A. | Collagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
| 1290 | Th1042 | Collagenase | MKRKCLSKRLMLAITMATIF Full view | 255 | Ic | Hematological | Xiaflex | Auxilium | Sterile lyophilized powder (white cake) | Intralesional Injection | N.A. | Collagen alpha-1(I) chain,Collagen alpha-1(II) chain,Collagen alpha-1(III) chain,Collagen alpha-2(I) chain |
| 1305 | Th1043 | Rasburicase | SAVKAARYGKDNVRVYKVHK Full view | 255 | Ic | Metabolic/Genetic | Elitek | Sanofi-Synthelabo Inc | Sterile, white to off-white, lyophilized powder | Intravenous administration | Antihyperuricemic Agents, Gout suppressants | Uric acid |
| 1306 | Th1043 | Rasburicase | SAVKAARYGKDNVRVYKVHK Full view | 255 | Ic | Metabolic/Genetic | Fasturtec | N.A. | Powder and solvent that are made upto make solution. | Intravenous administartion | Antihyperuricemic Agents, Gout suppressants | Uric acid |
| 1316 | Th1044 | Adalimumab | Light-chain:DIQMTQS< Full view | 230 | Ic | Immunological | Humira | Abbott Laboratories | Sterile, preservative-free solution | Subcutaneous administration | Immunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | Tumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
| 1317 | Th1044 | Adalimumab | Light-chain:DIQMTQS< Full view | 230 | Ic | Osteological | Humira Pen | Abbott Laboratories | Sterile, preservative-free solution | Subcutaneous injection | Immunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | Tumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
| 1337 | Th1048 | Pegaspargase | MEFFKKTALAALVMGFSGAA Full view | 255 | Ic | Cancer | Oncaspar | Enzon Inc | Solution | Intravenous or Intramuscular administration | Antineoplastic Agents | L-asparagine |
| 1381 | Th1059 | Hyaluronidase | MWTGLGPAVTLALVLVVAWA Full view | 476 | Ic | Adjunct Therapy | HYLENEX | Baxter Healthcare Corporation | Sterile, clear, colorless, nonpreserved, ready for use solution. | Human Injection Subcutaneous use | Adjuvants, Anesthesia and Permeabilizing Agents | N.A. |
| 1419 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | BOTOX | Allergan | Sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strainClostridium botulinum type A | Intramuscular, intradetrusor and intradermal use | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1420 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Dysport | Ipsen Pharmaceuticals | Sterile vial for reconstitution | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1421 | Th1070 | Botulinum Toxin Type A | MPFVNKQFNYKDPVNGVDIA Full view | 1296 | Ic | Neurological Disorder | Xeomin | MERZ AESTHETICS | Sterile white to off-white lyophilized powder after reconstitution with preservative-free 0.9% Saline for Injection. | Intramuscular Injection | Neuromuscular Blocking Agents, Anti-Wrinkle Agents and Antidystonic Agents | Growth hormone receptor |
| 1428 | Th1072 | Streptokinase | MKNYLSFGMFALLFALTFGT Full view | 440 | Ic | Metabolic/Haemetological | Streptase | CSL Behring | Sterile, purified preparation formulated as lypholized powder | Intravenous and intracoronary administration. | Fibrinolytic Agents and Thrombolytic Agents | N.A. |
| 1477 | Th1097 | Alglucosidase Alfa | AHPGRPRAVPTQCDVPPNSR Full view | 882 | Ic | Metabolic | LUMIZYME | Genzyme | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with 10.3 Ml Sterile Water for Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Cation-dependent mannose-6-phosphate receptor,Glycogen |
| 1621 | Th1134 | Asparaginase Erwinia Chrysanthemi | ADKLPNIVILATGGTIAGSA Full view | 327 | Ic | Hormonal | Erwinaze | EUSA Pharma | Sterile, lyophilized, white powder in vials. | Intramuscular injection | Enzymes | N.A. |
| 1622 | Th1135 | Ocriplasmin | Truncated heavy chai Full view | 251 | Ic | Eye Disorder | Jetrea | ThromboGenics NV | Sterile, clear and colorless solution with no preservatives | Intravitreal injection | Ophthalmics | Fibronectin,Alpha-2-macroglobulin,Alpha-2-antiplasmin |
| 1623 | Th1136 | Glucarpidase | ALAQKRDNVLFQAATDEQPA Full view | 393 | Ic | Hormonal | Voraxaze | BTG International | Sterile, preservative-free, white lyophilized powder in single-use vials | Intravenous injection | Enzymes | Methotrexate |
| 1637 | Th1143 | Fibrinolysin Aka Plasmin | Fibrinolysin heavy c Full view | 786 | Ic | Hematological | Elase | N.A. | N.A. | N.A. | N.A. | N.A. |
| 1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
| 1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
| 1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
| 1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
| 1820 | Th1211 | Ixekizumab | NA Full view | 0 | Ic | Infectious Disease | Taltz | Eli lilly | Sterile, preservative free, clear and colorless to slightly yellow Solution | Subcutaneous | NA | NA |